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Background-—Nearly 50% of patients with heart failure (HF) have preserved LV ejection fraction, with interstitial ﬁbrosis and
cardiomyocyte hypertrophy as early manifestations of pressure overload. However, methods to assess both tissue characteristics
dynamically and noninvasively with therapy are lacking. We measured the effects of mineralocorticoid receptor blockade on tissue
phenotypes in LV pressure overload using cardiac magnetic resonance (CMR).
Methods and Results-—Mice were randomized to L-nitro-x-methyl ester (L-NAME, 3 mg/mL in water; n=22), or L-NAME with
spironolactone (50 mg/kg/day in subcutaneous pellets; n=21). Myocardial extracellular volume (ECV; marker of diffuse interstitial
ﬁbrosis) and the intracellular lifetime of water (sic; marker of cardiomyocyte hypertrophy) were determined by CMR T1 imaging at
baseline and after 7 weeks of therapy alongside histological assessments. Administration of L-NAME induced hypertensive heart
disease in mice, with increases in mean arterial pressure, LV mass, ECV, and sic compared with placebo-treated controls, while LV
ejection fraction was preserved (>50%). In comparison, animals receiving both spironolactone and L-NAME (“L-NAME+S”) showed
less concentric remodeling, and a lower myocardial ECV and sic, indicating decreased interstitial ﬁbrosis and cardiomyocyte
hypertrophy (ECV: 0.430.09 for L-NAME versus 0.250.03 for L-NAME+S, P<0.001; sic: 0.420.11 for L-NAME groups versus
0.120.05 for L-NAME+S group). Mice treated with a combination of L-NAME and spironolactone were similar to placebo-treated
controls at 7 weeks.
Conclusions-—Spironolactone attenuates interstitial ﬁbrosis and cardiomyocyte hypertrophy in hypertensive heart disease. CMR
can phenotype myocardial tissue remodeling in pressure-overload, furthering our understanding of HF progression. (J Am Heart
Assoc. 2014;3:e000790 doi: 10.1161/JAHA.114.000790)
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N
early 50% of incident heart failure occurs in the
presence of preserved left ventricular ejection fraction
(HF-pEF).
1 In patients with HF-pEF, both cardiomyocyte
hypertrophy and elevated interstitial myocardial collagen
content are prominent features of tissue remodeling.
2,3
However, therapies speciﬁcally directed at interstitial ﬁbrosis
and hypertrophy (eg, phosphodiesterase-5 inhibition and
spironolactone) have had limited efﬁcacy in treating HF-
pEF,
4,5 possibly due to late application of therapies (eg, after
development of irreversible tissue-level changes). Further-
more, reliance on LV hypertrophy (LVH) and its regression to
stratify risk has limitations: regression of LVH (by blood
pressure control) does not fully normalize cardiac prognosis
or incident HF.
6,7 In this context, assessing tissue ﬁbrosis and
cardiomyocyte hypertrophy non-invasively in pathologic LV
remodeling – speciﬁcally alongside therapies that target these
key pathologies – would be fundamental to pre-clinical drug
development in HF-pEF, and for targeting patients with
greatest potential beneﬁt.
Giventheimportanceofﬁbrosisasatarget forpreventionat
thetransitiontoHF-pEF,increasingclinicalinteresthasfocused
on the use of mineralocorticoid receptor (MR) antagonist
therapy in the treatment of HF-pEF.
8 In animal models of
pressure-overload hypertrophy, spironolactone prevents inter-
stitial ﬁbrosis, cellular and organ-level hypertrophy, and
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ORIGINAL RESEARCHprevents development of HF.
9 Although MR antagonism leads
toregressionofLVhypertrophyinhypertensiveindividuals,
10,11
there are conﬂicting results on the clinical and physiological
beneﬁts of spironolactone in established HF-pEF.
5,12
In this study, we developed a noninvasive CMR-based
technique to measure the modiﬁability of myocardial tissue
phenotypes in mice during the induction of hypertension (via
L-nitro-x-methyl ester/L-NAME-treated mice), a well-estab-
lished model of hypertensive heart disease and HF-pEF. This
study extends our method to phenotype ﬁbrosis and cardio-
myocyte hypertrophy concurrently with a therapy – the ﬁrst
step in translating this imaging technique to human applica-
tions in HF-pEF.
Methods
Animal Models
Wild-type mice (mean body weight 37.86.4 g, Taconic) were
randomly assigned to 2 experimental groups: (1) L-NAME
(“L-NAME”;n=22),which included L-NAMEinthedrinkingwater
(3 mg/mL; Sigma, USA) for 7 weeks, and (2) L-NAME and
spironolactone (“L-NAME+S”;n =21) with L-NAME (3 mg/mL;
Sigma,USA)inthedrinkingwater,andspironolactone(50 mg/
kg per day) delivered by subcutaneous pellets (Innovative
Research of America) implanted in the subscapular region as
previouslydescribed.
13,14(Animalsinthe L-NAMEgroupdidnot
have subcutaneous pellets.) Animals were kept under standard
conditions withnormalchow andwater adlibitum.Noninvasive
tail blood pressures were obtained at baseline and after
7 weeks of treatment using a volume-pressure recording
tail-cuff technique
15 (CODA-1, Kent Scientiﬁc). CMR was
performed at baseline and after 7 weeks of treatment (L-NAME
and L-NAME+S). Blood samples were collected immediately
after each CMR study for blood hematocrit determination
(i-STAT). Animals were euthanized following the second CMR
study,andtheheartswereexcisedforhistologicalanalysis.The
same strain of mice, undergoing the same experimental
protocol as the L-NAME group, but receiving only tap water
alone for 7 weeks as placebo, had previously been studied in
our laboratory as controls (n=15).
16 The study protocol and
animal care conformed to the Guide for the Care and Use of
Laboratory Animals from the National Institutes of Health (NIH
PublicationNo.85-23,Revised1996).TheStandingCommittee
on Animal Care and Use at Harvard University approved the
study protocol.
Histopathologic Analysis
Heart tissues were ﬁxed with buffered 10% formalin solution
(Fisher Scientiﬁc). Sections stained with ﬂuoresceinisothiocy-
anate-conjugated (FITC-) wheat germ agglutinin to delineate
the cell membrane were used for cardiomyocyte size deter-
mination.
17 All sections were scanned with ScanScope
scanners (Aperio Technologies, Inc), and whole-slide images
were sampled to a ﬁnal resolution of 1.0 lm/pixel. Measure-
ments of (minor) cardiomyocyte diameter Dmin and major
cardiomyoctye-diameter Dmaj (equivalent to the cardiomyo-
cyte length) were obtained by image analysis of FITC-wheat
germ agglutinin stained sections. Ten measurements of Dmaj
and Dmin were made in each of the anterior, septal, lateral,
and inferior wall sections of the left ventricle. Cardiomyocyte
volume was calculated assuming a cell shape in the form of a
prolate ellipsoid,
18–21 using the median Dmin and Dmaj.
Connective tissue volume fraction was quantiﬁed on sections
stained with Masson’s trichrome stain, using a semi-auto-
matic pixel color intensity algorithm in the Aperio Spectrum
software to quantify pixels stained in blue.
Cardiac Magnetic Resonance Imaging
Anesthetized mice (isoﬂuorane1% to 2.5% in oxygen from a
precision vaporizer) were positioned prone in a water-heated
cradle in a dedicated MRI system for small animal imaging
(4.7 T Bruker BioSpin). Cine CMR images were acquired with
prospective electrocardiographic and respiratory gating
(model 1025L, SAII). For left ventricular (LV) size and function,
short-axis cine fast gradient echo images were acquired with
full ventricular coverage (repetition time TR 5.9 ms; echo time
TE 2.2 ms; temporal resolution 12 to 15 ms; in-plane spatial
resolution 100 to 120 lm9180 to 210 lm; 1 mm slice
thickness, no gap). Simpson’s rule was used to calculate LV
volumes, mass, and LV ejection fraction (LVEF). LV volumes
and mass were indexed by body weight. Gadolinium diethy-
lenetriamine-pentacetic acid (Magnevist, Berlex) was admin-
istered subcutaneously in multiple stages up to a cumulative
dose of 0.5 mmol/kg. Myocardial and blood T1s were
measured in a mid short-axis slice once precontrast, and at
least 4 times postcontrast using a Look-Locker technique, and
no earlier than 4 minutes after contrast administration as
described previously
22 (TR 2.5 ms; TE 1.8 ms; ﬂip angle=10°,
in-plane resolution 190 lm, 1 mm slice thickness). Signal
intensity versus time curves were used to determine T1 by
non-linear least-squares ﬁtting to an analytical expression for
the magnitude signal measured during the inversion recov-
ery,
22 and correction for the radiofrequency pulse effects on
the inversion recovery.
23
The reciprocal of T1 (R1=1/T1) for each myocardial
segment was analyzed as a function of R1 in the blood pool.
Myocardial R1, shows a sublinear dependence on R1 in blood
when the relaxation rate in blood approaches the rate of
exchange of water across the transcytolemmal barrier (on the
order of 1/sic)—the rate of water exchange across the cell
membrane then effectively becomes a bottleneck for further
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Hincreases of the myocardial R1. This allows a determination of
the intracellular lifetime, using as model a 2-space water-
exchange (2SX) model of equilibrium transcytolemmal water
exchange to obtain myocardial extracellular volume (ECV) and
the intracellular lifetime of water (sic). ECV and sic were both
independent parameters of the 2SX model.
16,22,24
The intracellular lifetime of water, sic depends on the mean
time for a water molecule to diffuse to the cell membrane. It
can be shown that sic is proportional to the volume-to-surface
ratio (V/S),
24,25 with V/S being on the order of the cell
diameter in the case of cardiomyocytes, which have a length-
to-diameter ratio of 4:1. This means that with the elongated
shape of cardiomyocytes, the intracellular lifetime is primarily
sensitive to changes in cell diameter.
16
Statistical Analyses
StatisticalanalysiswasperformedusingSAS9.3(SASInstitute)
or R (version 3.01, R Foundation; http://www.R-project.org/).
Data are presented as meansstandard deviation. Continuous
variableswerecomparedbetweenthe2 L-NAME-treatedgroups
of mice using t tests. Linear mixed effects (LME) regression
models(usingpackage“lme4”inR)werebuiltforvariableswith
repeated measures (eg, ECV and LV parameters) to test the
effects of treatment and time (ie, difference between baseline
and follow-up). Experimental group, study time-point (baseline
or follow-up), and their interaction were included as ﬁxed
effects in each LME model. A random mouse-speciﬁc intercept
accounted for correlations of measurements within each
mouse. For variables with repeated measurements P values
are for comparisons of least squares means for the factors of
said linear mixed effects models (using package “lmerTest” in
R). Therefore, for each variable with repeated measurements,
oneandthesamelinearmixedeffectsmodelwasusedtoobtain
P values for comparisons between groups at baseline and at
follow-up,andforcomparisonswithinagroupbetweenbaseline
and follow-up. For the histological variables with only one
measurement per animal, P values were obtained by Tukey’s
“Honest Signiﬁcant Difference” Method. Linear correlations
were assessed by Pearson’s correlation coefﬁcient. Multivar-
iatelinearregression models werebuiltformyocardialECVand
intracellular lifetime of water (sic) to test whether at follow-up
the treatment effect of spironolactone was signiﬁcant, with
simultaneous adjustment by mean arterial pressure.
Results
LV Hypertrophy, Fibrosis and Cardiomyocyte
Hypertrophy From L-NAME
Table summarizes the hemodynamic, CMR, and histological
parameters at baseline and after 7 weeks of L-NAME therapy
with and without spironolactone. An example of how the T1
measurements allowed the simultaneous determination of
ECV and intracellular lifetime is shown in Figure 1. There were
no signiﬁcant differences in cardiac structure, function, or
CMR-derived tissue phenotype (by intracellular lifetime of
water or ECV shown in Figures 2 and 3) at baseline between
the 2 groups. (There were also no signiﬁcant differences at
baseline when the controls were included.) Administration of
L-NAME induced hypertension,
26–28 as expected, with an
increase in mean arterial pressure from 86.87.4 mm Hg at
baseline to 124.46.1 mm Hg after 7 weeks of L-NAME
therapy (P<0.001). In response to hypertension, LV mass
increased in mice treated with L-NAME (16319 lg for
L-NAME versus 9914 lg for placebo-treated controls,
P<0.001), accompanied by a modest decrease in LV systolic
function (LVEF 518% for L-NAME versus 603% for controls,
P<0.001). LV mass-to-volume increased in L-NAME treated
mice (concentric remodeling). There were no signiﬁcant
changes in indexed LV mass or function in the control group.
The myocardial ECV, a CMR marker of interstitial ﬁbrosis,
increased after 7 weeks of L-NAME treatment (0.430.09 in
L-NAME at follow-up versus 0.260.03 in controls at follow-
up, P<0.001). The intracellular lifetime of water by CMR (sic), a
marker of cardiomyocyte hypertrophy, was increased after
7 weeks of L-NAME as compared with controls (0.420.11
for L-NAME versus 0.180.08 versus controls, P<0.001).
Effects of Spironolactone on Interstitial Fibrosis
and Cardiomyocyte Hypertrophy
Spironolactone treatment successfully abrogated the develop-
mentofhypertensionandhypertensiveheartdiseaseinanimals
treated with L-NAME, withareductioninmean arterialpressure
andLVmassrelative tomicereceivingsolely L-NAME(Table).In
comparison with L-NAME-treated mice, animals receiving both
spironolactone and L-NAME showed a lower myocardial ECV
and sic, indicating decreased interstitial ﬁbrosis and cardio-
myocyte hypertrophy (myocardial ECV: 0.430.09 for L-NAME
versus 0.250.03 for L-NAME+S, P<0.001; sic: 0.420.11 for
L-NAME groups versus 0.120.05 for L-NAME+S group).
Indeed, at follow-up, myocardial ECV and sic in mice receiving
both L-NAMEandspironolactonewerenotsigniﬁcantlydifferent
from controls (Figures 2 and 3). The differences in ECV and sic
between L-NAME and L-NAME+S groups remained highly
signiﬁcant at follow-up when adjusted by the baseline mea-
surements,usingaLMEmodel,andthisalsoremainedthecase
when the control group was included. The on-therapy effect of
spironolactone on myocardial ECV and sic remained signiﬁcant
after adjustment for mean arterial pressure in linear regression
(myocardial ECV: multiple R
2 adjusted to MAP=0.71, P<0.001;
sic: multiple R
2 adjusted to MAP=0.77, P<0.001). Concomitant
administration of spironolactone and L-NAME returned the
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measured by histology or CMR.
ECV correlated strongly with the LV mass-to-volume ratio,
a marker of concentric remodeling (r=0.62, P<0.001). The
marker of cardiomyocyte hypertrophy, sic, also correlated with
LV mass-to-volume ratio (r=0.54, P<0.001).
Histological Measurements and Relation to CMR
Markers
The histological measurements of connective tissue volume
fraction and the cardiomyocyte volume-to-surface ratio
(Figure 4), showed changes between groups, which paralleled
the differences for ECV and sic, respectively. Overall, there was
a strong association between ECV and histological ﬁbrosis
(r=0.879, P<0.01; Figure 5A), and between sic and cardiomyo-
cyte (minor) diameter (r=0.892, P<0.01; Figure 5B). Mice
treated with L-NAME alone averaged the highest volume-to-
surface ratio (32.11.9 in L-NAME at follow-up versus
24.71.5 in controls, P<0.001, and also versus 25.31.4 in
L-NAME+S, P<0.001), and the highest cardiomyocyte volume
(77.412.9 in L-NAME versus 42.36.1 in controls, P<0.001
and also versus, 476i nL-NAME+S, P<0.001), paralleling the
increaseofECVandsicbetween L-NAME+Sand L-NAMEgroups.
Discussion
The principal ﬁnding of our study is that CMR measurements
of extracellular volume fraction and intracellular lifetime of
water sensitively track changes in tissue phenotype with anti-
remodeling therapy in a mouse model of hypertensive heart
disease. This work extends previous results from our labora-
tory validating ECV and sic in pressure overload
16,22 by
demonstrating the modiﬁability of these indices with inter-
Table. Hemodynamic, MRI and Histological Measurements at Baseline and Follow-Up in Mice Treated With L-NAME and With or
Without Spironolactone Pre-Treatment
Baseline Follow-Up (7 Weeks)
Placebo
(n=14)
L-NAME
(n=22)
L-NAME+S
(n=21)
P
Value
Placebo
(n=14) L-NAME (n=17)
L-NAME+S
(n=18) P Value
Body weight, g 37.62.5 37.12.6 38.82.16 0.02 44.284.5** 402.0**
,†† 433.6** 0.01
HR, bpm 511112 50289 47888 0.35 47260 44748* 47451 0.13
Mean arterial blood pressure, mm Hg 91.08.0 86.87.4 87.06.8 0.93 89.26.4 1246.1**
,†† 1075.3** <0.001
MRI
LVEF, % 57.83.7 59.73.34 60.03.65 0.84 60.33.2 51.38.2**
,†† 52.77.5**
,†† 0.63
LVEDV, lL 12830.1 1029.4
†† 99.36.1
†† 0.46 11126.2* 11834* 9024
† 0.01
LVESV, lL5 4 13.1 41.15.5
†† 39.95.6
†† 0.55 4412.0* 57 19**
,†† 4416 0.04
LVmass, lg 94.516.3 91.712.2 88.211.8 0.46 98.514.4 16319**
,†† 96 13 <0.001
LV mass-to-volume ratio 0.770.17 0.900.12 0.880.09 0.54 0.940.29* 1.470.38**
,†† 1.140.33**
,† 0.01
LV mass index to body weight, lg/g 3.400.79 2.470.31 2.270.23 0.08 2.540.69* 4.070.42**
,†† 2.300.36 <0.001
MRI extracellular volume fraction
(ECV)
0.270.03 0.270.04 0.280.05 0.59 0.260.03 0.430.09**
,†† 0.250.03 <0.001
MRI intracellular life time of water, s 0.140.07 0.170.09 0.160.06 0.57 0.180.08 0.420.11**
,†† 0.120.05 <0.001
Histology
Connective tissue fraction (histology)
[%]
—— — — 2.60.6% 8.51.6%
†† 2.70.8% <0.001
Cardiomyocyte area, lm
2/10
3 —— — — 17.01.4 23.92.6
†† 18.41.6 <0.001
Volume-to-surface ratio —— — — 24.71.5 32.11.9
†† 25.31.4 <0.001
Cardiomyocyte volume by histology,
10
49lm
3
—— — — 4267 7 13
†† 476 <0.001
Column denoted by “P value” shows P-values for L-NAME vs L-NAME+S. All P values for variables with repeated measurements (ie, baseline and follow-up measurements) were obtained
from one and the same linear mixed effects model for the variable, which had study (baseline or follow-up), animal group, and their interaction as ﬁxed effects. For the histological variables
with only one measurement per animal P values were obtained by Tukey’s “Honest Signiﬁcant Difference” Method. Data for placebo group are for reference, were part of previous
publication, and were included in the analysis with mixed effects models. LVEF indicates left ventricular ejection fraction; L-NAME, Nx–nitro-L-arginine-methyl-ester; LVEDV, left ventricular
end-diastolic volume; LVESV, left ventricular end-systolic volume; S, spironolactone.
For comparisons of follow-up vs baseline, *P<0.05 and **P<0.01.
For comparisons at baseline or follow-up vs placebo group
†P<0.05 and
††P<0.01 for L-NAME and L-NAME+S groups.
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When added to L-NAME therapy, spironolactone blocked the
increase in myocardial ECV and sic observed with L-NAME
therapy alone. Importantly, these changes were independent
of on-therapy reduction in blood pressure in mice treated with
spironolactone, and occurred in the presence of a clinically
normal LV ejection fraction (mean LVEF>50% in all groups).
Collectively, these results establish the utility of CMR imaging
to diagnose phenotypes during the transition from hyperten-
sive heart disease to HF-pEF.
Hypertension is the strongest modiﬁable risk factor for
development of HF and subsequent cardiac mortality.
29,30 In
animalmodels,afterloadexcessfromhypertensionengendersa
characteristic genetic and morphologic ventricular response,
fromcellularandorgan-levelhypertrophyandinterstitialﬁbrosis
to ultimate ventricular dilatation and failure.
31–33 Speciﬁcally,
interstitial ﬁbrosis may mark the transition from compensated
cellular and organ-level pathologic hypertrophy to HF in both
animals and at-risk patients.
31,34–36 However, a residual risk of
HFinpatientsafterregressionofLVHremains,
6,7suggestingthe
presence of adverse, tissue-level phenotypes beyond LVH. In
addition, the limited beneﬁt of novel, anti-ﬁbrotic therapies in
older patients with long-standing hypertension and established
HF-pEF
5,37,38 further suggests that demonstrating the beneﬁts
of anti-ﬁbrotic therapies earlier in the course of HF (eg, stage A
HF) may be critical.
The imperative to identify early phenotypes in the progres-
sion to HF has partially motivated recent work utilizing T1
mapping CMR to examine interstitial ﬁbrosis in pressure
overload.
39 In a study of 10 rats exposed to angiotensin II to
promote LVH, Messroghli and colleagues used Look-Locker
inversion recovery T1 mapping to demonstrate elevated ECV in
parallel to histologic ﬁbrosis after induction of hypertension.
40
Our group has published data demonstrating increased ECV in
mice exposed to pharmacologically induced hypertension (eg,
L-NAME
22) and mechanical pressure overload (eg, transverse
Figure 1. Illustration of dependence of myocardial R1 on R1 in
blood. This example is from a study in a mouse at follow-up after
treatment with L-NAME and spironolactone. The dashed line
corresponds to the standard method of determining ECV from the
ratio of the change of R1 in myocardial tissue divided by the
change of R1 in blood (a linear model). At higher contrast
concentrations the myocardial R1 increases more slowly than
predicted by this linear model, because the exchange of water
across the sarcolemmal membrane becomes the rate-limiting
step for myocardial relaxation, thereby resulting in a myocardial
R1 that is lower than expected for fast exchange conditions
(double arrow). ECV and intracellular lifetime were determined by
a 2-space model of water exchange across the (sarcolemmal)
membrane between the 2 spaces. ECV indicates extracellular
volume; L-NAME, Nx–nitro-L-arginine-methyl-ester.
Figure 2. The extracellular volume fraction (ECV) increased with the build-up of interstitial ﬁbrosis in the
mice treated with L-NAME, compared to L-NAME+spironolactone. At baseline there were no signiﬁcant
differences in ECV between controls (“placebo”), L-NAME, and L-NAME+spironolactone groups. The ECV
data for the control group are from a previous study, using the same experimental protocol. At follow-up
ECV was not signiﬁcantly different between controls and L-NAME+spironolactone (P=0.48). L-NAME
indicates Nx–nitro-L-arginine-methyl-ester.
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Haortic constriction
16). In parallel, similar T1 mapping experi-
ments have demonstrated increased ECV and its association
withhistologicﬁbrosisinpressureoverload,includingHF-pEF
22
and aortic stenosis.
41 Despite this wealth of emerging data on
T1 mapping in pressure overload, the extension of T1 mapping
CMR into a therapeutic realm remains limited by 2 major
obstacles: (1) data on the prevention or reversibility of ECV in
appropriate animal models or patients is lacking and (2) the
ability to look at cardiomyocyte hypertrophy (an early occur-
rence in pressure overload) is absent.
Accordingly, we studied the effect of mineralocorticoid
antagonist therapy with spironolactone on L-NAME-induced
hypertensive heart disease, demonstrating abrogation of
interstitial ﬁbrosis, cardiomyocyte hypertrophy, and whole-
organ LVH when spironolactone was initiated at the time of
L-NAME. Extending our previous report in this model,
16,22 we
demonstrate for the ﬁrst time that dynamic changes in
myocardial ECV and sic with spironolactone are highly
associated with coordinate histological changes within the
myocardium. These results establish ECV and sic as noninva-
sive, modiﬁable indices of tissue-level changes within the
heart relevant to pre-clinical HF. Although small studies have
demonstrated reduction in collagen turnover with mineralo-
corticoid antagonism in HF-pEF,
42 myocardial ECV provides an
accurate reﬂection of the expansion of the extra-cellular
space due to the aggregate collagen accumulation – not
turnover – within the heart, likely more speciﬁc to the
underlying substrate for ventricular stiffness and clinical HF.
Our results are timely in the context of increasing attention
on the role of mineralcorticoid (MR) antagonist therapy in
HF-pEF.
8 MR antagonist therapy reduces interstitial ﬁbrosis
and cellular hypertrophy in animal models, improving
ventricular performance and survival independent of blood
pressure lowering or serum aldosterone concentration.
9,43 In
the largest published clinical study of spironolactone in HF-
pEF, Edelmann and colleagues reported a reduction of LV
mass with slight improvement in echocardiographic diastolic
dysfunction with spironolactone; unfortunately, this did not
translate to improvement in functional capacity.
5,37 In small
studies, circulating markers of myocardial ﬁbrosis are reduced
with MR antagonism.
42 Given the complex, life-long exposure
to proﬁbrotic comorbidities that track closely with HF-pEF (eg,
hypertension, diabetes, obesity), these results suggest that
true beneﬁts of MR antagonism may be realized with
preventative application earlier in the course of disease,
before irreversible interstitial ﬁbrosis has taken hold. In this
light, the prevalence and reversibility of an aberrant myocar-
dial tissue phenotype by CMR demonstrated here provides a
backdrop for future investigations in antiﬁbrotic therapies at
an earlier stage of disease, possibly allowing the direct
observation of therapeutic efﬁcacy before frank LV dysfunc-
tion, hypertrophy, or HF. In this context, we eagerly await the
results of TOPCAT (Treatment of Preserved Cardiac Function
after Heart Failure with an Aldosterone Antagonist study;
clinical trials identiﬁer NCT00094302).
8
Our results should be viewed in the context of study
design. Although we do not have spironolactone drug levels to
conﬁrm efﬁcacy, we observe a lower average blood pressure
with spironolactone. While we do not measure reversibility of
established ﬁbrosis, our demonstration of the modiﬁability of
myocardial ECV and sic is the ﬁrst, essential step in
determining a “threshold” beyond which MR antagonism fails
to affect the heart. In addition, the placebo-treated controls
used in this study were previously published and not imaged
Figure 3. The intracellular lifetime of water (sic), a measure of cardiomyocyte diameter, increased
signiﬁcantly in the mice treated with L-NAME, compared to L-NAME+spironolactone, consistent with the
histological appearance of cardiomyocyte hypertrophy. At baseline there was no signiﬁcantly difference in
sic between controls, L-NAME, and L-NAME+spironolactone groups. The sic data for the control group are
from a previous study, using the same experimental protocol. At follow-up, sic in the L-NAME+spirono-
lactone group was not signiﬁcantly different from controls (P=0.34). L-NAME indicates Nx–nitro-L-arginine-
methyl-ester.
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large experience with normal mice,
44 there is no systematic
reason why concurrent imaging would yield different results.
Finally, more detailed assessments of diastolic function (eg,
CMR tagging), HF (via lung-heart weight), or changes in
myocardial stiffness (eg, by invasive pressure-volume loop
analysis) were not performed in this study. However, preven-
tion of ﬁbrosis with spironolactone (versus L-NAME alone)
with a preserved LVEF suggests that spironolactone normal-
ized the structural myocardial phenotype.
The measurements of ECV and sic reported in this study
relied on multiple (4 to 5) measurements of T1 after contrast
injection. This is more time-consuming than protocols utilized
in previous studies for determination of ECV alone, which
generally rely on two T1 measurements (1 pre- and 1 post-
contrast).
45,46 The shorter protocol based on 2 T1 measure-
ments assumes that the exchange of water across the
sarcolemmal membrane (described by the intracellular lifetime
of water sic) is negligible.
22 For determination of sic,i ti s
necessary to measure T1 when fast water exchange conditions
no longer apply in order to observe an effect from the ﬁnite
intracellular lifetime. The model for ﬁtting the change of the
myocardial R1 as a function of R1in blood has both ECV and sic
as adjustable parameters and requires multiple postcontrast
measurements for a reliable estimation of sic.
16 A further
limitation is the fact that in myocardial tissue, cardiomyocytes
account for approximately 90% of the intracellular volume,
meaning the measured intracellular lifetime of water will have
some slight bias from the contribution of other cell types.
To our knowledge, our results are the ﬁrst noninvasive
demonstration that a comprehensive myocardial tissue phe-
notype quantifying cardiomyocyte hypertrophy and interstitial
ﬁbrosis are variable with therapy in a model of pressure
overload. These results extend the use of CMR to detect early
disease myocardial changes into a therapeutic realm: the
ability to noninvasively phenotype tissue-based LV remodeling
Wheat Germ Agglu nin Stain
Masson’s TrichromeStain
12 X
70μm
12 X
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20 X
50μm
20 X
50μm
L-NAME L-NAME + SPIRO
L-NAME L-NAME + SPIRO
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C
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D
Figure 4. Short-axis, mid-level sections of cardiac tissue from the left ventricle (LV) in mice treated with L-
NAME (A and C), and spironolactone and L-NAME (B and D), after 7 weeks of L-NAME. Short-axis sections
stained with Masson’s trichrome stains in (A) and (B) illustrate relative abundant interstitial ﬁbrosis
(appearing blue) in L-NAME, as compared to L-NAME+spironolactone. Adjacent slices in the same mice in
(C) and (D) were stained with ﬂuorescein isothiocyanate-conjugated (FITC) wheat germ agglutinin to
delineate cell membranes. With L-NAME alone, mice showed cardiomyocyte hypertrophy, compared to L-
NAME+spironolactone. The cardiomyocyte diameters in the anterior, lateral, inferior and septal LV
segments were signiﬁcantly larger in L-NAME compared to L-NAME+spironolactone (P<0.001). L-NAME
indicates Nx–nitro-L-arginine-methyl-ester.
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development of HF – is fundamental to furthering our
understanding of pathobiology of HF and its reversal.
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